Published in Mol Cancer Res on August 07, 2014
PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med (2015) 1.16
Role of microRNAs in maintaining cancer stem cells. Adv Drug Deliv Rev (2014) 0.97
TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell (2016) 0.84
TGF-β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells. Elife (2017) 0.81
Regulation of Bone Morphogenetic Protein Signaling by ADP-ribosylation. J Biol Chem (2016) 0.76
A TGFβ-miR-182-BRCA1 axis controls the mammary differentiation hierarchy. Sci Signal (2016) 0.76
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. Biomed Res Int (2016) 0.75
There and Back Again: The Middle Earth of DNA Repair. Mol Cancer Res (2016) 0.75
Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. PLoS One (2016) 0.75
TGFbeta and miRNA regulation in familial and sporadic breast cancer. Oncotarget (2017) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
TGFbeta in Cancer. Cell (2008) 17.44
TGFbeta signaling in growth control, cancer, and heritable disorders. Cell (2000) 12.38
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
Triple-negative breast cancer. N Engl J Med (2010) 11.39
SMAD proteins control DROSHA-mediated microRNA maturation. Nature (2008) 9.67
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
The many substrates and functions of ATM. Nat Rev Mol Cell Biol (2000) 5.46
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell (2010) 3.12
The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56
CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res (2012) 2.50
Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 2.40
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18
Targeting the TGF beta signaling network in human neoplasia. Cancer Cell (2003) 2.16
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95
Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene (2010) 1.92
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest (2013) 1.76
Noncanonical mismatch repair as a source of genomic instability in human cells. Mol Cell (2012) 1.63
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res (2010) 1.61
I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. Methods Mol Biol (2012) 1.59
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res (2010) 1.56
Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics (2008) 1.45
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res (2010) 1.38
Limiting the persistence of a chromosome break diminishes its mutagenic potential. PLoS Genet (2009) 1.38
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One (2010) 1.36
Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol Biol (2007) 1.23
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle (2013) 1.23
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol (2010) 1.22
miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst (2013) 1.18
Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells. Mol Cancer Res (2010) 1.16
Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J Biol Chem (2009) 1.08
Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem (2007) 1.06
Abnormal response of ataxia-telangiectasia cells to agents that break the deoxyribose moiety of DNA via a targeted free radical mechanism. Carcinogenesis (1983) 1.02
Mammalian cell HPRT gene mutation assay: test methods. Methods Mol Biol (2012) 1.01
Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther (2012) 1.00
Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res (2013) 0.94
The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Histol (2006) 0.91
Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle. Genes Dev (2013) 0.88
PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair in vitro. DNA Repair (Amst) (2011) 0.87
PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1. J Exp Clin Cancer Res (2010) 0.85
Defining the DNA mismatch repair-dependent apoptotic pathway in primary cells: evidence for p53-independence and involvement of centrosomal caspase 2. DNA Repair (Amst) (2010) 0.84
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. Oncogenesis (2013) 0.79
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. Int J Oncol (2013) 0.77